Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Divestments (2016 - 2017)

Lisata Therapeutics' Divestments history spans 4 years, with the latest figure at -$206.0 for Q4 2017.

  • For Q4 2017, Divestments fell 100.02% year-over-year to -$206.0; the TTM value through Sep 2018 reached -$206.0, down 100.02%, while the annual FY2017 figure was -$189000.0, N/A changed from the prior year.
  • Divestments reached -$206.0 in Q4 2017 per LSTA's latest filing, up from -$70.5 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $65.3 million in Q2 2017 to a low of -$70.5 million in Q3 2017.